Petrylak, D. P., Ratta, R., Matsubara, N., Korbenfeld, E., Gafanov, R., Mourey, L., Todenhöfer, T., Gurney, H., Kramer, G., Bergman, A. M., Zalewski, P., Santis, M. D., Armstrong, A. J., Gerritsen, W., Pachynski, R., Byun, S. S., Retz, M., Levesque, E., McDermott, R., Bracarda, S., Manneh, R., Levartovsky, M., Li, X. T., Schloss, C., Poehlein, C. H., Fizazi, K. (2025). Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01283